Today: 21 May 2026
GigaDevice Semiconductor stock price: What to watch for 603986 A-shares as memory crunch bites
8 February 2026
2 mins read

GigaDevice Semiconductor stock price: What to watch for 603986 A-shares as memory crunch bites

Shanghai, Feb 8, 2026, 09:44 GMT+8 — Market’s shut.

  • Class A shares of GigaDevice Semiconductor ended at 276.17 yuan, slipping 0.6%.
  • Investors are watching to see if the global memory-chip shortage will push device prices higher and dent sales volumes.
  • On Feb. 11, shareholders are set to vote—items on the agenda include caps on related-party transactions and the appointment of an overseas auditor.

GigaDevice Semiconductor Inc. Class A shares on the Shanghai exchange slipped 0.6% to finish at 276.17 yuan Friday. During the session, the stock moved in a 268.20-280.43 yuan range. Over the past year, shares have surged nearly 99%.

Monday’s focus is shifting to memory chips — not just one company’s news, but the semiconductors squeezed into smartphones, PCs, and servers, now running scarce. Apple hasn’t announced any iPhone price hikes, though CEO Tim Cook pointed to “different levers that we can push” as he acknowledged higher memory costs for the company. Reuters

This has direct implications for GigaDevice, which operates in the same supply chain. When pricing power improves, revenue can climb—even if demand isn’t steady. “This the biggest question for the industry now,” IDC senior research director Nabila Popal said, with the memory crunch putting handset manufacturers in a tough spot: protect margins, or keep prices stable. Reuters

On paper, chips are seeing a brighter outlook. The Semiconductor Industry Association projects global semiconductor sales topping $1 trillion this year. Memory chips? The group expects a 34.8% jump, projecting $223.1 billion in 2025 as AI demand sends prices higher and shortages bite.

SIA CEO John Neuffer didn’t mince words: “my orders are completely full,” he told Reuters. He flagged that soaring demand is now reaching sectors of the supply chain that typically don’t get much attention. Reuters

China’s caught up in it as well. Intel and AMD have told clients there that certain server CPUs are facing long lead times. Sources familiar with the holdups say the scramble to ramp up AI infrastructure is putting the pinch elsewhere—especially on memory chips, where prices are still climbing.

GigaDevice produces non-volatile memory—including flash chips—and controllers tied to those products, Bloomberg reports. Its main shares are listed as 603986 on the Shanghai Stock Exchange, with a Hong Kong listing as well.

When GigaDevice listed in Hong Kong back in January, the stock shot up roughly 40% on its first trading day — a clear sign investors are betting hard on China’s push for chip independence. According to Reuters, the company holds the No.2 spot worldwide in NOR flash memory, commanding an 18.5% slice of that market.

The next marker for the company is Feb. 11. According to a Hong Kong filing, GigaDevice is scheduled for its 2026 first extraordinary general meeting in Beijing. On the agenda: proposed caps on daily related-party transactions for the first half of 2026 and the selection of an overseas accounting firm.

The company, in a Jan. 23 statement, disclosed that its related-party deal involves buying DRAM products under foundry agreements with ChangXin Technology Group and subsidiaries, setting a transaction ceiling at $221 million—roughly 15.47 billion yuan—for the first half.

But that same shortage pushing chip prices higher can also crimp volumes. Phone and PC makers, reluctant to pass on added costs, might pull back on production instead. That spells a rapid hit for suppliers — memory players included.

Shanghai reopens Monday, and the focus is squarely on memory prices—will they keep moving the needle? Investors are also bracing for any fresh filings before the Feb. 11 shareholder vote that could shift the picture for GigaDevice’s Class A shares.

Stock Market Today

  • SpaceX IPO Filing Reveals Financials, Musk Could Become First Trillionaire
    May 20, 2026, 7:08 PM EDT. SpaceX filed for an initial public offering (IPO), disclosing its finances and board members for the first time. The company reported $18.7 billion in revenue for 2025, up 33% year-on-year, but posted a net loss of $4.9 billion, reversing a $791 million profit in 2024. First-quarter 2026 losses reached $4.3 billion on $4.7 billion revenue. The IPO, trading as SPCX, may become the largest ever, potentially boosting Elon Musk's wealth to trillionaire status. SpaceX aims to fund its ambitious plans including Starlink satellite network expansion, AI infrastructure, and establishing extraterrestrial colonies.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Zhongji Innolight stock slides nearly 4% into China’s Monday open — what traders watch next
Previous Story

Zhongji Innolight stock slides nearly 4% into China’s Monday open — what traders watch next

Windows 11 printer alert: Microsoft tightens the screws on legacy V3/V4 drivers in 2026
Next Story

Windows 11 printer alert: Microsoft tightens the screws on legacy V3/V4 drivers in 2026

Go toTop